The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | The potential of targeting mutant calreticulin with antibodies in MPNs
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, explores the interaction between mutated calreticulin (CALR) and the thrombopoietin receptor in myeloproliferative neoplasms (MPNs) like myelofibrosis (MF) and essential thrombocythemia (ET). Prof. Rinaldi highlights the potential of immunotherapeutic approaches, including monoclonal antibodies, to target this mechanism, particularly for the treatment of MF. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
